(0.33%) 5 171.75 points
(0.31%) 38 951 points
(0.22%) 18 041 points
(0.87%) $78.79
(1.31%) $2.17
(0.95%) $2 330.50
(2.60%) $27.38
(1.00%) $975.00
(-0.07%) $0.928
(-0.38%) $10.83
(-0.24%) $0.795
(-0.12%) $91.34
Live Chart Being Loaded With Signals
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products...
Stats | |
---|---|
आज की मात्रा | 26 806.00 |
औसत मात्रा | 51 037.00 |
बाजार मूल्य | 406.69B |
EPS | €8.63 ( 2023-06-30 ) |
Last Dividend | €3.00 ( 2023-08-18 ) |
Next Dividend | €0 ( N/A ) |
P/E | 22.91 |
ATR14 | €2.62 (2.86%) |
मात्रा सहसंबंध
Novo Nordisk A/S सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध |
---|
10 सबसे अधिक नकारात्मक सहसंबंध |
---|
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
Novo Nordisk A/S सहसंबंध - मुद्रा/वस्त्र
Novo Nordisk A/S वित्तीय
Annual | 2022 |
राजस्व: | €176.95B |
सकल लाभ: | €148.51B (83.92 %) |
EPS: | €24.51 |
FY | 2022 |
राजस्व: | €176.95B |
सकल लाभ: | €148.51B (83.92 %) |
EPS: | €24.51 |
FY | 2021 |
राजस्व: | €140.80B |
सकल लाभ: | €117.14B (83.20 %) |
EPS: | €20.79 |
FY | 2020 |
राजस्व: | €126.95B |
सकल लाभ: | €106.01B (83.51 %) |
EPS: | €18.05 |
Financial Reports:
No articles found.
Novo Nordisk A/S Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€4.25 (N/A) |
€0 (N/A) |
€8.15 (N/A) |
€0 (N/A) |
€3.00 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.670 | 2002-03-13 |
Last Dividend | €3.00 | 2023-08-18 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 30 | -- |
Total Paid Out | €100.58 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.88 | -- |
Div. Sustainability Score | 6.14 | |
Div.Growth Potential Score | 4.38 | |
Div. Directional Score | 5.26 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
KTA.DE | Ex Dividend Junior | 2023-05-30 | Annually | 0 | 0.00% | |
V6C.DE | Ex Dividend Junior | 2023-06-01 | Annually | 0 | 0.00% | |
DR0.DE | Ex Dividend Junior | 2023-06-30 | Sporadic | 0 | 0.00% | |
NKE.DE | Ex Dividend Knight | 2023-09-01 | Quarterly | 0 | 0.00% | |
4PN.DE | Ex Dividend Knight | 2023-06-22 | Quarterly | 0 | 0.00% | |
FMV.DE | Ex Dividend Junior | 2023-08-15 | Quarterly | 0 | 0.00% | |
PSAN.DE | Ex Dividend Junior | 2023-05-24 | Sporadic | 0 | 0.00% | |
AP2.DE | Ex Dividend Knight | 2023-11-22 | Quarterly | 0 | 0.00% | |
HP3A.DE | Ex Dividend Junior | 2023-06-21 | Annually | 0 | 0.00% | |
SOW.DE | Ex Dividend Junior | 2023-05-18 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.351 | 1.500 | 2.98 | 4.47 | [0 - 0.5] |
returnOnAssetsTTM | 0.251 | 1.200 | 1.635 | 1.962 | [0 - 0.3] |
returnOnEquityTTM | 0.869 | 1.500 | 1.460 | 2.19 | [0.1 - 1] |
payoutRatioTTM | 0.422 | -1.000 | 5.78 | -5.78 | [0 - 1] |
currentRatioTTM | 0.824 | 0.800 | -0.880 | -0.704 | [1 - 3] |
quickRatioTTM | 0.635 | 0.800 | -0.971 | -0.777 | [0.8 - 2.5] |
cashRatioTTM | 0.175 | 1.500 | -0.141 | -0.211 | [0.2 - 2] |
debtRatioTTM | 0.0884 | -1.500 | 8.53 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -18.83 | 1.000 | -8.08 | -8.08 | [3 - 30] |
operatingCashFlowPerShareTTM | 23.78 | 2.00 | 2.07 | 4.15 | [0 - 30] |
freeCashFlowPerShareTTM | 17.38 | 2.00 | 1.308 | 2.62 | [0 - 20] |
debtEquityRatioTTM | 0.285 | -1.500 | 8.86 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.841 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.392 | 1.000 | 4.16 | 4.16 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 4.01 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.715 | 0.800 | 8.57 | 6.85 | [0.5 - 2] |
Total Score | 6.14 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 40.52 | 1.000 | 6.01 | 0 | [1 - 100] |
returnOnEquityTTM | 0.869 | 2.50 | 4.51 | 2.19 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 17.38 | 2.00 | 4.21 | 2.62 | [0 - 30] |
dividendYielPercentageTTM | 0.440 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 23.78 | 2.00 | 2.07 | 4.15 | [0 - 30] |
payoutRatioTTM | 0.422 | 1.500 | 5.78 | -5.78 | [0 - 1] |
pegRatioTTM | 0.142 | 1.500 | -2.38 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.496 | 1.000 | 0.0917 | 0 | [0.1 - 0.5] |
Total Score | 4.38 |
Novo Nordisk A/S
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं